Formulary Watch |

ICER Gives Cell Therapy for Post-Transplant Complications High Rating

November 1, 2024

Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.

October 31, 2024 3:32 PM

white blood cells © Best - stock.adobe.com

FDA Grants Accelerated Approval of Scemblix for Newly-Diagnosed CML

October 30, 2024 7:25 PM

FDA Accepts Organon’s Application for Prolia Biosimilar

October 30, 2024 7:00 PM

FDA Accepts Resubmission of Translarna NDA for Duchenne

October 30, 2024 3:13 PM

All News

Biologics License Application Resubmitted for Prademagene Zamikeracel

GoodRx Offers Weight Loss Drug Qsymia for $149 at Retail Pharmacies

October 29, 2024

Prademagene zamikeracel (pz-cel) could be a new treatment for rare genetic disease recessive dystrophic epidermolysis bullosa (RDEB).

Rigel Warns Physicians About Fatal Infections from Gavreto

October 29, 2024

Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with reductions in 24-hour mean systolic blood pressure.

FDA Approves IV Form of Stelara Biosimilar Selardsi

October 24, 2024

Gavreto used to treat metastatic RET fusion-positive non-small cell lung cancer and RET fusion-positive thyroid cancer.

FDA Approves First-in-Class Drug for Gastric Cancer

October 23, 2024

This week’s approval expands Seldardsi indications to treat adults with Crohn’s disease and ulcerative colitis.

Karen Lynch Steps Down as CEO of CVS Health

October 18, 2024

Zolbetuximab — now with the brand name Vyloy — is a monoclonal antibody to treat patients with advanced gastric and gastroesophageal cancers.

FDA Approves Imuldosa, the Fifth Stelara Biosimilar

October 18, 2024

David Joyner has been appointed president and CEO of CVS Health effective immediately.

FDA Approves Hympavzi for Hemophilia A and B

October 14, 2024

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

FDA Approves Itovebi for Metastatic Breast Cancer

October 11, 2024

Hympavzi is the first anti-tissue factor pathway inhibitor approved in the United States for hemophilia.

Are PBMs Putting GLP-1 Drugs on Their Formularies?

October 11, 2024

Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination with Ibrance and fulvestrant. It will have a cost of $22,867 for a 28-day cycle.

IQVIA: Patients Unlikely to See Savings from Medicare’s Drug Price Negotiation

October 11, 2024

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.

FDA Accepts NDA for Menopause Drug, Elinzanetant

October 10, 2024

The IQVIA analysis finds that the impact of drug price negotiation on patients’ out-of-pocket spending could also be smaller than expected.

Trilliant Report Finds the Money Spent on Healthcare Doesn’t Provide Value

October 9, 2024

If approved, elinzanetant would be another non-hormonal option for menopausal women seeking hot flash relief.

UnitedHealthcare Adds Deductibles to Medicare Part D for 2025

October 7, 2024

Sanjula Jain of Trilliant Health talks about how employers are best positioned to demand value for money from the U.S. healthcare system.

NDA Resubmitted for Dry Eye Treatment Reproxalap

October 3, 2024

UnitedHealthcare is adding deductibles to Part D prescriptions on certain formulary tiers as a result of plan design changes from the Inflation Reduction Act.

October 3, 2024

Dry eye disease affects up to 15% of the U.S. population and is one of the largest markets in the ophthalmology field.

Stelara Biosimilar Otulfi Approved by FDA to Treat Multiple Autoimmune Disorders

Blue Shield of California to Offer Humira Biosimilar Idacio

October 1, 2024

Otulfi is the fourth Stelara biosimilar to be approved by the FDA.

FDA Approves Dupixent for Patients with COPD

October 1, 2024

Blue Shield of California is purchasing Idacio for a net price of $525 per monthly dose, and most plan members will pay $0 out of pocket.

FDA Approves the Oral Medication KarXT for Schizophrenia

September 27, 2024

This is the sixth indication for Dupixent and the only biologic approved in the United States to treat COPD.

Survey Finds Payers are Looking for Change in Pharmacy Benefits

September 27, 2024

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.

Pfizer Withdraws Sickle Cell Drug Oxbryta from Market

September 26, 2024

PSG's Morgan Lee talks about how customers of the Big 3 PBMs report lower satisfaction across most measures, and they are less likely to recommend their PBM.

FDA Approves Second Drug to Treat Rare Neurodegenerative Disease

September 26, 2024

Clinical data suggests an imbalance in vaso-occlusive crises and fatal events that require further assessment, and the company said it will provide updates in the future.

Takeaways from Senate Hearing on Semaglutide Pricing

September 25, 2024

Aqneursa is the second drug approved within a week to treat Niemann-Pick Disease, Type C.

By Lauren Biscaldi

September 25, 2024

Novo Nordisk said it’s open to discussions with PBMs based on their commitments that a lower semgalutide list price would not impact formulary coverage.

The FTC Insulin Case is About Access — and Rebates